Phase I trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma (NBL)
| Autor: | Anne E. Hagey, Frank M. Balis, Susan L. Cohn, Elizabeth Fox, Peter C. Adamson, D. M. Medina, Brigitte C. Widemann, John M. Maris, Y. Cai, K. A. Meek |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Cancer Research
Pediatrics medicine.medical_specialty business.industry Sulfonamide (medicine) macromolecular substances Pharmacology medicine.disease Microtubule polymerization Bioavailability chemistry.chemical_compound Oncology chemistry Maximum tolerated dose Neuroblastoma medicine Colchicine business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:8527-8527 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.8527 |
| Popis: | 8527 Background: ABT-751 is an orally bioavailable sulfonamide that binds to the colchicine site on β-tubulin and inhibits microtubule polymerization. In adults, the maximum tolerated dose (MTD) is... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|